Induction Therapy for Acute Myelogenous Leukemia with Idarubicin/Cytosine Arabinoside and Mitoxantrone/Etoposide in “Response-Adapted” Sequence
With conventional induction chemotherapy 47%–72% of adult patients with acute myelogenous leukemia (AML) achieve complete remission (CR). However, the probability of continuous CR ranges from 8% to 45% at 3 years . Most of the chemotherapeutic protocols for induction treatment consist of cytosine arabinoside (Ara-C) combined with an anthracycline such as daunorubicin. One possibility to improve the induction remission rate is the administration of new agents with higher antileukemic activity. Furthermore, for patients not responding to the first-line chemotherapy, an alternate regimen with non-cross-resistant cytostatic drugs should be considered in the early phase of induction treatment.
KeywordsOncol Etoposide Cytosine Anthracycline Cytarabine
Unable to display preview. Download preview PDF.
- 1.Büchner T et al. (1987) Postinduction and preremission chemotherapy alternatives for adult AML: three multicenter studies of the AML cooperative group. In: Büchner T et al. (eds) Acute leukemias. Springer, Berlin Heidelberg New York, pp 57–63 (Haematology and blood transfusion, vol 30 )CrossRefGoogle Scholar